Physician profile

Abdulaziz Joury

New Orleans, LA

NPI 1528412335

$3,562.03

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$290.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Biotronik INC. $1,299.97 2020
Astrazeneca Pharmaceuticals LP $623.57 2019-2022
Pfizer INC. $410.40 2019-2022
Boston Scientific Corporation $290.60 2024 Lux-Dx Insertable Cardiac Monitor
E.R. Squibb & Sons, L.L.C. $287.93 2020-2022
Astellas Pharma US INC $246.10 2021
Esperion Therapeutics, INC. $207.68 2020-2022
Amgen INC. $140.19 2021-2022
Medtronic, INC. $31.32 2021
Lantheus Medical Imaging, INC. $24.27 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abdulaziz Joury

$3,562.03

in general payments reported 2019-2025

Years
2019-2024
Top company
Biotronik INC.

https://glasscript.com/doctor/7229026/abdulaziz-joury

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.